{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T13:14:41Z","timestamp":1763471681699,"version":"3.45.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1202","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Direct oral anticoagulants (DOACs) have emerged as an alternative to warfarin for stroke prevention in atrial fibrillation (AF) patients. This study aimed to evaluate anticoagulation recommendations at discharge for newly diagnosed AF patients and investigate associated clinical factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed the electronic medical records of adult patients hospitalized with new-onset AF at a large tertiary medical centre between January 2014 and April 2025. We examined patient demographics, clinical characteristics, laboratory indices, and anticoagulation recommendations at discharge. Logistic regression models were used to identify factors associated with DOAC prescription and trends over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study consisted of 3857 adult patients. DOAC prescription rates significantly increased over time, reaching 100% by 2023 and 2024. Patients with chronic kidney disease (CKD) were less likely to receive DOACs. Apixaban was the most frequently prescribed DOAC, particularly in older patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates a significant shift towards DOACs as the preferred anticoagulation therapy for newly diagnosed AF patients, aligning with current guidelines. However, CKD remains a factor influencing DOAC prescription.<\/jats:p>\n                    <jats:p>Key messages What is already known on this topic: Atrial fibrillation (AF) increases stroke risk, traditionally managed with warfarin but now increasingly treated with direct oral anticoagulants (DOACs). However, research is limited on anticoagulation recommendations at discharge in newly diagnosed AF patients, highlighting the need to understand clinical factors influencing these decisions. What this study adds: This study reveals a complete shift to DOAC prescription for newly diagnosed AF patients, with apixaban preferred in older patients. Although studies in recent years suggest that DOACs can be safe and effective in patients with chronic kidney disease (CKD), we find that DOACs prescriptions were less prevalent in these patients in comparison with warfarin. How this study might affect research, practice or policy: These findings suggest an opportunity to enhance clinician awareness and guidelines around DOAC use in elderly or CKD patients, potentially guiding future research and policy to improve AF management in these subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/postmj\/qgaf096","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:50:53Z","timestamp":1749196253000},"page":"1344-1350","source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulation discharge treatment recommendations in patients admitted with a first-time diagnosis of atrial fibrillation"],"prefix":"10.1093","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-9110","authenticated-orcid":false,"given":"Orly","family":"Efros","sequence":"first","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center , Derech Sheba, Ramat Gan 52621 , Central District,","place":["Israel"]},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University , Chaim Levanon St 55, Tel Aviv 39040 , Central District,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center , Derech Sheba, Ramat Gan 52621 , Central District,","place":["Israel"]},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University , Chaim Levanon St 55, Tel Aviv 39040 , Central District,","place":["Israel"]},{"name":"Amalia Biron Research Institute of Thrombosis & Hemostasis, Sheba Medical Center , Derech Sheba, Central District, Ramat Gan 52621 ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aharon","family":"Lubetsky","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center , Derech Sheba, Ramat Gan 52621 , Central District,","place":["Israel"]},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University , Chaim Levanon St 55, Tel Aviv 39040 , Central District,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omri","family":"Cohen","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center , Derech Sheba, Ramat Gan 52621 , Central District,","place":["Israel"]},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University , Chaim Levanon St 55, Tel Aviv 39040 , Central District,","place":["Israel"]},{"name":"Amalia Biron Research Institute of Thrombosis & Hemostasis, Sheba Medical Center , Derech Sheba, Central District, Ramat Gan 52621 ,","place":["Israel"]},{"name":"Department of Medicine and Surgery, University of Insubria , Via Ravasi, 221100 Varese (VA) ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadan","family":"Lalezari","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center , Derech Sheba, Ramat Gan 52621 , Central District,","place":["Israel"]},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University , Chaim Levanon St 55, Tel Aviv 39040 , Central District,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7853-2029","authenticated-orcid":false,"given":"Shelly","family":"Soffer","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , 39 Jabotinsky Street, Petah-Tikva 4941492 , Central District,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liat Waldman","family":"Radinsky","sequence":"additional","affiliation":[{"name":"National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center , Derech Sheba, Ramat Gan 52621 , Central District,","place":["Israel"]},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University , Chaim Levanon St 55, Tel Aviv 39040 , Central District,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyal","family":"Klang","sequence":"additional","affiliation":[{"name":"The Division of Data-Driven and Digital Medicine (D3M), Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, New York, NY 10029-6574 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7107-0549","authenticated-orcid":false,"given":"Aya","family":"Berman","sequence":"additional","affiliation":[{"name":"Dan Petah-Tikvah District at Clalit Health Service , 101 Arlozorov Street, Tel Aviv 6209804 ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noam","family":"Barda","sequence":"additional","affiliation":[{"name":"ARC Innovation Center, Digital Health Innovation Department, Sheba Medical Center , Derech Sheba, Ramat-Gan 52621 ,","place":["Israel"]},{"name":"Software and Information Systems Engineering, Ben Gurion University of the Negev , Ben-Gurion Boulevard, P.O. Box 653, Be\u2019er Sheva 8410501 , Southern District,","place":["Israel"]},{"name":"Epidemiology, Biostatistics and Community Health Services, Ben-Gurion University of the Negev, Ben-Gurion Boulevard, P.O. Box 653, Be\u2019er Sheva 8410501 , Southern District,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2025111808115365700_ref1","doi-asserted-by":"publisher","first-page":"VI","DOI":"10.1177\/23969873221099478","article-title":"European stroke organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin","volume":"7","author":"Rubiera","year":"2022","journal-title":"Eur Stroke J"},{"key":"2025111808115365700_ref2","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.105.595140","volume-title":"Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence","author":"Miyasaka","year":"2006"},{"key":"2025111808115365700_ref3","doi-asserted-by":"crossref","first-page":"e000279","DOI":"10.1136\/openhrt-2015-000279","article-title":"NOACs versus warfarin for stroke prevention in patients with AF: A systematic review and meta-analysis","volume":"3","author":"Hicks","year":"2016","journal-title":"Open Heart"},{"key":"2025111808115365700_ref4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bcp.14404","article-title":"Warfarin and food, herbal or dietary supplement interactions: A systematic review","volume":"87","author":"Tan","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025111808115365700_ref5","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/bcp.14608","article-title":"Warfarin dosing algorithms: A systematic review","volume":"87","author":"Asiimwe","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025111808115365700_ref6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5811\/westjem.2014.12.22933","article-title":"Anticoagulation drug therapy: A review","volume":"16","author":"Harter","year":"2015","journal-title":"Western J Emerg Med"},{"key":"2025111808115365700_ref7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the Management of Patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025111808115365700_ref8","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: The ARISTOPHANES study","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke."},{"key":"2025111808115365700_ref9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2025111808115365700_ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2022.04.023","article-title":"Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations","volume":"101","author":"Imberti","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2025111808115365700_ref11","doi-asserted-by":"publisher","first-page":"e2242964","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"},{"author":"Sheba Medical Center","key":"2025111808115365700_ref12"},{"key":"2025111808115365700_ref13","doi-asserted-by":"publisher","first-page":"17559","DOI":"10.1161\/JAHA.120.017559?download=true","article-title":"Direct oral anticoagulant use: A practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025111808115365700_ref14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2025111808115365700_ref15","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2025111808115365700_ref16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2025111808115365700_ref17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2025111808115365700_ref18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2025111808115365700_ref19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med"},{"key":"2025111808115365700_ref20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: Patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"2025111808115365700_ref21","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the Spectrum of kidney function: Patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"key":"2025111808115365700_ref22","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"2025111808115365700_ref23","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: A multicenter randomized controlled trial","volume":"32","author":"de Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025111808115365700_ref24","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2215\/CJN.01260213","article-title":"Dabigatran and kidney disease: A bad combination","volume":"8","author":"Knauf","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025111808115365700_ref25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation","volume":"175","author":"Lau","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/101\/1202\/1344\/63547509\/qgaf096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/101\/1202\/1344\/63547509\/qgaf096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T13:11:58Z","timestamp":1763471518000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/101\/1202\/1344\/8171705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":25,"journal-issue":{"issue":"1202","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgaf096","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"type":"print","value":"0032-5473"},{"type":"electronic","value":"1469-0756"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,6,23]]}}}